

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application.

LISTING OF CLAIMS:

Claim 1. (Original) A method of treatment of a human or non-human animal subject to combat inflammation arising from a condition associated with pain or a condition not associated with pain, said method comprising administering to said subject an effective amount of a physiologically tolerable strontium compound.

Claim 2. (~~Original~~Currently Amended) A—The method as claimed in claim 1, wherein said strontium compound is administered to the surface of the skin.

Claim 3. (~~Original~~Currently Amended) A—The method as claimed in ~~either of claims~~claim 1—~~and~~2, wherein said inflammation is not associated with pain.

Claim 4. (~~Original~~Currently Amended) A—The method as claimed in ~~any one of claims~~claim 1—~~to~~3, wherein said inflammation is not associated with a sporting injury.

Claim 5. (~~Original~~Currently Amended) A—The method as claimed in ~~any one of claims~~claim 1—~~to~~4, wherein said administration is not oral.

Claims 6-7. (Cancelled).

Claim 8. (Currently Amended) ~~Use~~The method as claimed in ~~either of claims~~6 and 7~~claim~~1, wherein said medicament strontium compound is administered further contains with a skin penetration enhancing agent.

Claim 9. (Currently Amended) ~~Use~~The method as claimed in claim 8, wherein said skin penetration enhancing agent is dimethylsulphoxide.

PRELIMINARY AMENDMENT
NS Entry of PCT/GB2004/001369

Claim 10. (Currently Amended) ~~Use~~ The method as claimed in ~~any one of claims 6 to 8~~claim 1, wherein of a said strontium compound is selected from the group consisting of strontium chloride, strontium acetate and strontium nitrate.

Claim 11. (Currently Amended) ~~Use~~ The method as claimed in ~~any one of claims 6 to 10~~claim 1, wherein said strontium compound is a strontium complex, e.g., with a chelating agent.

Claim 12. (Currently Amended) ~~Use~~ The method as claimed in claim 11, wherein said chelating agent is present in at least 2% mol excess relative to strontium.

Claim 13. (Currently Amended) ~~Use~~ The method as claimed in claim 12, wherein said chelating agent is present in an excess of at least 50% mol relative to strontium.

Claim 14. (Currently Amended) ~~Use~~ The method as claimed in claim 1~~any one of claims 6 to 13~~, wherein said inflammation is associated with acne vulgaris.

Claim 15. (Currently Amended) ~~Use~~ The method as claimed in ~~any one of claims 6 to 13~~claim 1, wherein said inflammation is associated with psoriasis.

Claim 16. (Currently Amended) ~~Use~~ The method as claimed in ~~any one of claims 6 to 13~~claim 1, wherein said inflammation is associated with radiation therapy.

Claim 17. (Currently Amended) ~~Use~~ The method as claimed in ~~any one of claims 6 to 13~~claim 1, wherein said inflammation is associated with arthritis.

Claim 18. (New) The method as claimed in claim 2, wherein said inflammation is not associated with pain.